Active Clinical Trials

Clinical trials are at the heart of our work to bring innovative medicines to people with a particular disease or condition. Learn more about the active studies conducted by Novartis including opportunities to get involved.

Showing 175 results
  • Sort by
  • Study title
  • Condition
  • Phase
  • Location
Study title Condition Phase Location NCT ID

A Study of DII235 in Adults With Elevated Lipoprotein(a)

 		Lipoprotein Disorder Phase2 Japan
United States 		NCT07235046

Observational Study on Lutetium (177Lu) Vipivotide Tetraxetan to Treat Metastatic Castration Resistant Prostate Cancer

 		Metastatic Castration Resistant Prostate Cancer Italy NCT07093801

Evaluation of 1-Year Clinical Outcomes With Early Inclisiran Initiation in Post-MI Patients

 		Myocardial Infarction Russia NCT07142265

Study to Assess the Pharmacokinetics, Safety, and Tolerability of Iptacopan in Pediatric PNH Patients

 		Paroxysmal Nocturnal Hemoglobinuria (PNH) Phase3 Brazil
Colombia
Germany
Italy
Netherlands
United States
View all
 NCT06934967

Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN

 		Primary Immunoglobulin A Nephropathy (IgAN) Phase3 China
Israel
Japan
United States
View all
 NCT06994845

Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes

 		Acute Coronary Syndrome Phase3 Japan NCT07102628

Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors

 		Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer, HR+/HER2- Ductal and Lobular Breast Cancer, Triple Negative Breast Cancer, Colorectal Cancer, Soft Tissue Sarcoma Phase1 Israel NCT07261631

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of OJR520 in Healthy Volunteers and Participants With Chronic Kidney Disease

 		Chronic Kidney Disease Phase1 United States NCT07235059

TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

 		Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Phase1, Phase2 South Korea
United States 		NCT07190300

A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC

 		PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy Phase1, Phase2 Australia NCT07226986